Mesenchymal Cell c-MPL Expression for Platelet Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets are inefficient, requiring long times and large quantities of cells, and face challenges such as refractory responses due to HLA and HPA incompatibilities, with existing techniques like iPS cells taking over 50 days and direct reprogramming involving gene introduction with safety concerns.
Innovation Solution
A method involving culturing mesenchymal cells, such as preadipocytes, in a basic medium with TPO or derivatives like Romiplostim and Eltrombopag olamine to promote c-MPL receptor expression on the cell surface, enhancing differentiation efficiency into megakaryocytes and platelets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If platelets are produced using conventional blood donation methods, then the supply depends on donor availability, but the storage life is limited to about three days and supply amount varies
Solution Approach 1:
The invention changes the fundamental parameter of platelet production from in vivo blood donation to in vitro cell culture. By culturing mesenchymal stem cells with TPO and differentiation-inducing agents, platelets can be produced with extended storage life and controlled supply amounts independent of donor availability
Solution Approach 2:
The invention enables autologous platelet production where a patient's own mesenchymal stem cells are cultured and differentiated into platelets. This self-service approach eliminates immune rejection issues and provides personalized platelet supply without depending on blood donors
2Reliability
If platelets are produced from iPS cells to overcome HLA and HPA incompatibility, then immune rejection is reduced, but the production time requires at least about 50 days
Solution Approach 1:
The invention uses pre-established mesenchymal stem cell lines that are primed for differentiation. By maintaining these cells in culture and inducing differentiation when needed, the system eliminates the lengthy reprogramming process of iPS cells while still achieving autologous compatibility and reducing rejection risks
Solution Approach 2:
The invention extracts the essential feature of autologous compatibility from the iPS cell approach but separates it from the time-consuming reprogramming process. By using directly available mesenchymal stem cells from adipose tissue or bone marrow, the system achieves immune compatibility without the 50-day production timeline
3Loss of time
If direct reprogramming of fibroblasts is used to produce platelets, then production time is shortened to about 14 days, but gene introduction with safety concerns is required
Solution Approach 1:
The invention uses transient expression of differentiation-inducing factors in mesenchymal stem cells without permanent genetic modification. The cells are cultured with TPO and other agents that induce platelet production temporarily, avoiding the safety issues of integrating vectors while maintaining short production time
Solution Approach 2:
The invention uses mesenchymal stem cells as an intermediary between fibroblasts and platelets. Rather than directly reprogramming fibroblasts with genes, the system differentiates mesenchymal stem cells (which can be obtained without gene transfer) into megakaryocytes and platelets, eliminating the need for gene introduction while maintaining efficiency
4Ease of manufacture
If conventional platelet production methods are used, then the process is simple, but production efficiency is low and requires tens of thousands of petri dishes
Solution Approach 1:
The invention uses mesenchymal stem cells that can serve multiple functions: they can be expanded extensively in culture, differentiated into platelets, and used for multiple transfusions. This multi-functionality allows a single culture to produce sufficient platelets for many patients, dramatically improving production efficiency while maintaining procedural simplicity
Solution Approach 2:
The invention segments the platelet production process into distinct phases: expansion of mesenchymal stem cells, induction of megakaryocyte differentiation, and platelet release. This segmentation allows optimization of each phase independently, achieving high productivity while keeping the overall process manageable and scalable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient production of megakaryocytes and platelets with high c-MPL receptor expression, reducing production time and costs, and minimizing immune rejection risks by using autologous cells.
Implementation Method 1
culturing the mesenchymal cell in a mesenchymal cell culturing basic medium not comprising LDL cholesterol, insulin, 2-mercaptoethanol, an iron ion or an iron transporter, and comprising a c-MPL receptor active substance
Data Source
Figure 1
AI summary
An object of the present invention is to provide a method of simply and efficiently promoting expression of c-MPL on a surface of a mesenchymal cell. The present invention provides a method for producing a mesenchymal cell with promoted expression of a c-MPL receptor on the cell surface, comprising Step A of culturing the mesenchymal cell in a mesenchymal cell culturing basic medium comprising a c-MPL receptor active substance; and Step B of obtaining the mesenchymal cell with promoted expression of a c-MPL receptor on the cell surface.